Kisspeptin-10
Reproductive Health, Hormone Balance
In short
- A fragment of kisspeptin, the peptide that sits upstream of GnRH and is the master regulator of reproductive endocrinology.
- Its discovery reshaped understanding of puberty onset — loss-of-function mutations in its receptor cause failure of puberty.
- Has genuinely been studied in humans, including trials at Imperial College London on sexual and emotional brain processing.
- Very short half-life, measured in minutes.
- Not approved for any indication.
Structure
How it works
Kisspeptin signals through the KISS1R receptor (formerly GPR54) on GnRH neurons in the hypothalamus, stimulating GnRH release. GnRH then drives LH and FSH from the pituitary, which drive the gonads.
This places kisspeptin one level above GnRH in the reproductive hierarchy, and it is the point at which metabolic and environmental signals gate reproductive function.
Kisspeptin-10 is the shortest fragment retaining full receptor activity. Its brevity in circulation is a direct consequence of its size.
What the research shows
Human studies demonstrate that kisspeptin administration reliably increases LH secretion — the endocrine effect is well established.
Imperial College trials reported effects on brain activity in regions processing sexual and emotional stimuli, and studies in men with hypoactive sexual desire have reported behavioural signal.
It has been explored as a trigger for oocyte maturation in IVF, where it may reduce ovarian hyperstimulation risk compared with HCG — arguably its most promising clinical application.
No approval exists for any use.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — LH stimulation and neuroimaging studies | Intravenous infusion, commonly around 1 nmol/kg/hour | intravenous infusion | PubMed |
| Human — IVF oocyte maturation trigger studies | Single bolus doses; see source | subcutaneous | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 100–300 µg as needed | subcutaneous |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. The human studies overwhelmingly used intravenous infusion under clinical monitoring, not subcutaneous bolus injection. Route and delivery pattern differ substantially from community practice, and the minutes-long half-life means a bolus produces a very different exposure profile from an infusion.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
The research route is intravenous infusion. Subcutaneous injection is the community route with no supporting comparative data.
The extremely short half-life means any effect from a bolus is brief.
Side effects
Human trials report good tolerability, with no significant adverse effects at studied doses — this is genuine human safety data, uncommon here.
Because it stimulates the reproductive axis, effects on LH, testosterone, and oestradiol are expected rather than side effects as such.
Prolonged continuous kisspeptin exposure can desensitise KISS1R, the same pattern seen with GnRH — so repeated frequent dosing may work against itself. This has not been characterised for community dosing patterns.
Combinations
No established combinations. Combining with GnRH analogues or HCG stimulates the same axis at different levels, which is redundant rather than synergistic, and compounds desensitisation risk.
Research status
Genuinely important endocrinology. The kisspeptin/KISS1R system's role in puberty was a significant discovery, and the human trial programme at Imperial College is legitimate published clinical research.
What does not exist is any approved product or established therapeutic protocol.
Legal status
Not approved in any jurisdiction. Sold for research use only.
WADA status
Falls under WADA class S2 as a releasing factor acting on the gonadotropin axis, and under S0 as an unapproved substance. Treat as prohibited in sport.
Conclusion
Kisspeptin-10 sits at a genuinely important node in reproductive biology and has real human trial data behind it — more than most compounds here.
The gap is in how it is used: the studies infused it intravenously under monitoring, and the community injects boluses subcutaneously. Those are different interventions with the same molecule.
Sources
Track your own Kisspeptin-10 protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.